# MicroCHIPS

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/microchips

- Industry: Medical Devices & Equipment
- Headquarters: Waltham, US
- Website: www.mchips.com
- Total disclosed funding: $46M
- Latest round: Series G (Jan 7, 2010)
- Investors on record: 11

## About

MicroCHIPS Inc. specializes in developing innovative microchip solutions for medical applications, focusing on improving patient care through advanced technology and delivery systems.Founded in 1999 and headquartered in Waltham, US, MicroCHIPS Inc. creates microchip-based medical solutions. In November 2019, Daré Bioscience, Inc. acquired the company with a deal potentially worth up to USD 101.5 million, contingent on funding and sales goals. The firm has executed a total of 10 deals since its inception and was involved in its latest funding round in November 2019, raising USD 18.650 mn. The current company valuation stands at USD 72.773 mn.MicroCHIPS Inc. develops microchip technologies for medical applications, aiming to revolutionize patient treatment through enhanced drug delivery systems. Their solutions are designed to improve the efficiency and efficacy of healthcare treatments, targeting both patients and healthcare providers with a focus on reliability and ease of integration into existing medical frameworks.MicroCHIPS Inc. generates revenue primarily through its innovative medical technologies, which support healthcare providers in delivering precise treatments. The company’s revenue model encompasses direct sales of its microchip solutions and potential licensing agreements with industry partners, focusing on providing value through advanced medical applications.With the acquisition by Daré Bioscience, Inc., MicroCHIPS Inc. aims to leverage additional resources for expanding its product offerings and enhancing its technology. The company is focused on developing new microchip solutions tailored for emerging medical needs and plans to explore international markets to broaden its reach. The funding raised in the 2019 deal will support these initiatives, particularly in scaling operations and accelerating product development.

## Funding rounds

- Series G, Jan 7, 2010, $17M — Care Capital, Intersouth Partners, InterWest Partners, Polaris Partners, Novartis Venture Fund, Saints Capital, Whiz Partners, Flybridge Capital Partners, Medtronic
- Series F, Dec 1, 2006, $13M — Intersouth Partners, Polaris Partners, Novartis Venture Fund, Whiz Partners, Flybridge Capital Partners, Medtronic, Boston Scientific Ventures, Boston University Community Technology Fund
- Series B, May 20, 2002, $16M — Care Capital, Intersouth Partners, Polaris Partners, Flybridge Capital Partners, Boston University Community Technology Fund
- Seed, Jun 1, 1999 — Polaris Partners

## Investors

- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Seed, Series B, Series F, Series G
- Care Capital (https://capitalatlas.ai/funds/care-capital) — Series B, Series G
- Intersouth Partners (https://capitalatlas.ai/funds/intersouth-partners) — Series B, Series F, Series G
- Flybridge Capital Partners (https://capitalatlas.ai/funds/flybridge-capital-partners) — Series B, Series F, Series G
- Boston University Community Technology Fund — Series B, Series F
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series F, Series G
- Whiz Partners (https://capitalatlas.ai/funds/whiz-partners) — Series F, Series G
- Medtronic — Series F, Series G
- Boston Scientific Ventures (https://capitalatlas.ai/funds/boston-scientific-ventures) — Series F
- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series G
- Saints Capital (https://capitalatlas.ai/funds/saints-capital) — Series G